TMEM63B

Across TCGA pan-cancer cohorts, TMEM63B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM63B data layer compared with 19 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM63B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM63B expression acts as an unfavorable survival marker, although some lineages such as LUAD and SKCM show a favorable association.

LIHC, PRAD, and LUAD are the cancer types where TMEM63B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	All	0.868	0.273	.014	6	view →
SKCM	DFS	Median	All	0.488	0.195	.009	6	view →
UCEC	OS	Median	II,III,IV	1.000	0.467	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM63B–LIHC (OS)

Open the LIHC breakdown →